Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sickle-Cell Transfusions

Sickle-Cell Transfusions A trial designed to see whether children with sickle cell anemia at high risk for stroke could safely stop receiving periodic red blood cell transfusions after a minimum of 30 months was halted last month by the National Heart, Lung, and Blood Institute, in Bethesda, Md. Early results from the Stroke Prevention Trial (STOP) 2 trial indicated that stopping transfusions cannot be recommended (http://www.nhlbi.nih.gov). New findings indicate that stopping red blood cell transfusions in children with sickle cell anemia increases their stroke risk. (Photo credit: www.sciencesource.com) The importance of transfusions for sickle cell anemia was established in 1997 following the STOP 1 trial, which indicated that administering blood transfusions every 3 to 4 weeks to such children reduces their rate of first-time stroke by 90%. STOP 2, initiated in 2000, was expected to recruit 100 patients aged 2 to 18 years over a 6-year period. But the trial was terminated 2 years early with 79 patients enrolled because 14 of the 41 patients who had been randomly assigned to stop transfusions reverted to high risk of stroke and 2 patients had strokes. None of the patients who received transfusions reverted or had strokes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Sickle-Cell Transfusions

JAMA , Volume 293 (4) – Jan 26, 2005

Sickle-Cell Transfusions

Abstract

A trial designed to see whether children with sickle cell anemia at high risk for stroke could safely stop receiving periodic red blood cell transfusions after a minimum of 30 months was halted last month by the National Heart, Lung, and Blood Institute, in Bethesda, Md. Early results from the Stroke Prevention Trial (STOP) 2 trial indicated that stopping transfusions cannot be recommended (http://www.nhlbi.nih.gov). New findings indicate that stopping red blood cell transfusions in children...
Loading next page...
 
/lp/american-medical-association/sickle-cell-transfusions-6CsZ3dFqJO

References (1)

Publisher
American Medical Association
Copyright
Copyright © 2005 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.293.4.415-b
Publisher site
See Article on Publisher Site

Abstract

A trial designed to see whether children with sickle cell anemia at high risk for stroke could safely stop receiving periodic red blood cell transfusions after a minimum of 30 months was halted last month by the National Heart, Lung, and Blood Institute, in Bethesda, Md. Early results from the Stroke Prevention Trial (STOP) 2 trial indicated that stopping transfusions cannot be recommended (http://www.nhlbi.nih.gov). New findings indicate that stopping red blood cell transfusions in children with sickle cell anemia increases their stroke risk. (Photo credit: www.sciencesource.com) The importance of transfusions for sickle cell anemia was established in 1997 following the STOP 1 trial, which indicated that administering blood transfusions every 3 to 4 weeks to such children reduces their rate of first-time stroke by 90%. STOP 2, initiated in 2000, was expected to recruit 100 patients aged 2 to 18 years over a 6-year period. But the trial was terminated 2 years early with 79 patients enrolled because 14 of the 41 patients who had been randomly assigned to stop transfusions reverted to high risk of stroke and 2 patients had strokes. None of the patients who received transfusions reverted or had strokes.

Journal

JAMAAmerican Medical Association

Published: Jan 26, 2005

Keywords: blood transfusion,drepanocytes

There are no references for this article.